Abstract
Experimental evidences on the adaptive immune response in patients with hereditary hemorragic telagiectasia (HHT) are lacking. Here, we report in 9 patients with HHT a multiple deficit involving the intracellular expression of T helper (h)1-derived cytokines [Interferon (IFN)-γ, Interleukin (IL)-2 and Tumor Necrosis Factor (TNF)-α] and of monocyte- derived TNF-α. On the other hand, percentages of Th2-derived cytokines (IL-4, IL-5 and IL-10) were normal or, in some cases, above normality. Quite interestingly, monocyte-derived IL-10 was detectable in 5 out of 9 patients in a percentage of cells comparable to controls or exceeding normal levels. Taken together, these data point out, in HHT, an ablation of Th1-responses, while Th2-type cytokines are preserved, thus exerting either a suppressive effect on Th1-cells (via IL-4 and IL-10) or an antiinflammatory response on monocyte-derived TNF-α (via IL-10). Furthermore, monocytederived IL-10 may also contribute to the antiinflammatory activity seen in HHT. According to current literature even if patients with HHT do not exhibit certain diseases, such as autoimmune diseases, cancer and abnormal responses to pathogens, the observed immune deficits need to be diagnosed and therapeutically corrected.
Keywords: Cytokines, hereditary hemorrhagic teleangiectasia, monocytes, T-Lymphocytes
Current Pharmaceutical Design
Title: Ablation of T-Helper 1 Cell Derived Cytokines and of Monocyte-Derived Tumor Necrosis Factor-α in Hereditary Hemorrhagic Telangiectasia: Immunological Consequences and Clinical Considerations
Volume: 12 Issue: 10
Author(s): F. Resta, V. Triggiani, E. Jirillo, C. Sabba, L. Amati and M. E. Passeri
Affiliation:
Keywords: Cytokines, hereditary hemorrhagic teleangiectasia, monocytes, T-Lymphocytes
Abstract: Experimental evidences on the adaptive immune response in patients with hereditary hemorragic telagiectasia (HHT) are lacking. Here, we report in 9 patients with HHT a multiple deficit involving the intracellular expression of T helper (h)1-derived cytokines [Interferon (IFN)-γ, Interleukin (IL)-2 and Tumor Necrosis Factor (TNF)-α] and of monocyte- derived TNF-α. On the other hand, percentages of Th2-derived cytokines (IL-4, IL-5 and IL-10) were normal or, in some cases, above normality. Quite interestingly, monocyte-derived IL-10 was detectable in 5 out of 9 patients in a percentage of cells comparable to controls or exceeding normal levels. Taken together, these data point out, in HHT, an ablation of Th1-responses, while Th2-type cytokines are preserved, thus exerting either a suppressive effect on Th1-cells (via IL-4 and IL-10) or an antiinflammatory response on monocyte-derived TNF-α (via IL-10). Furthermore, monocytederived IL-10 may also contribute to the antiinflammatory activity seen in HHT. According to current literature even if patients with HHT do not exhibit certain diseases, such as autoimmune diseases, cancer and abnormal responses to pathogens, the observed immune deficits need to be diagnosed and therapeutically corrected.
Export Options
About this article
Cite this article as:
Resta F., Triggiani V., Jirillo E., Sabba C., Amati L. and Passeri E. M., Ablation of T-Helper 1 Cell Derived Cytokines and of Monocyte-Derived Tumor Necrosis Factor-α in Hereditary Hemorrhagic Telangiectasia: Immunological Consequences and Clinical Considerations, Current Pharmaceutical Design 2006; 12 (10) . https://dx.doi.org/10.2174/138161206776361372
DOI https://dx.doi.org/10.2174/138161206776361372 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Paracoccidioides spp. and Histoplasma capsulatum: Current and New Perspectives for Diagnosis and Treatment
Current Topics in Medicinal Chemistry Immunogenicity in Protein and Peptide Based-Therapeutics: An Overview
Current Protein & Peptide Science Biologics in Inflammatory Immune-mediated Systemic Diseases
Current Pharmaceutical Biotechnology Therapeutic Strategies in Autoimmune Diseases by Interfering with Leukocyte Endothelium Interaction
Current Pharmaceutical Design Basement Membrane Peptides: Functional Considerations and Biomedical Applications in Autoimmunity
Current Medicinal Chemistry Anti-TNF-α Antibody Therapies in Autoimmune Diseases
Current Topics in Medicinal Chemistry Editorial (Thematic Issue: Biologics in Autoimmune Diseases)
Current Pharmaceutical Biotechnology Obstructive Sleep Apnea and Autoimmune Rheumatic Disease: Is there Any Link?
Inflammation & Allergy - Drug Targets (Discontinued) Targeting Cytosolic Phospholipase A2α for Novel Anti-Inflammatory Agents
Current Medicinal Chemistry Synthetic Sphingosine 1-Phosphate Receptor Modulators - Opportunities and Potential Pitfalls
Current Topics in Medicinal Chemistry Systemic Sclerosis: Clinical Manifestations
Current Rheumatology Reviews Synthetic Peptides in the Diagnosis of Neurological Diseases
Current Protein & Peptide Science Molecular Phenotype of CXCL12β 3UTR G801A Polymorphism (rs1801157) Associated to HIV-1 Disease Progression
Current HIV Research Dendritic Cells and Immunomodulation: Role in Health and Disease
Current Immunology Reviews (Discontinued) miRNA Functions in Arthritis
Current Rheumatology Reviews Design, Synthesis and In Vitro Release Studies of Co-Drugs for Rheumatoid Arthritis
Inflammation & Allergy - Drug Targets (Discontinued) Interferon-beta Inhibits Th17 Cell Differentiation in Patients with Multiple Sclerosis
Endocrine, Metabolic & Immune Disorders - Drug Targets The Current Role and Therapeutic Targets of Vitamin D in Gastrointestinal Inflammation and Cancer
Current Pharmaceutical Design Involvement of Membrane Channels in Autoimmune Disorders
Current Pharmaceutical Design Animal Models of Central Nervous System Immune-Mediated Diseases: Therapeutic Interventions with Bioactive Peptides and Mimetics
Current Medicinal Chemistry